Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion
- 31 March 2012
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 142 (3) , 237-242
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Syk Activation of Phosphatidylinositol 3-Kinase/Akt Prevents HtrA2-dependent Loss of X-linked Inhibitor of Apoptosis Protein (XIAP) to Promote Survival of Epstein-Barr Virus+ (EBV+) B Cell LymphomasJournal of Biological Chemistry, 2011
- Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cellsBlood, 2011
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid ArthritisNew England Journal of Medicine, 2010
- Therapeutic Targeting of Syk in Autoimmune DiabetesThe Journal of Immunology, 2010
- The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationCancer, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus PatientsImmunity, 2010
- Novel Human Transitional B Cell Populations Revealed by B Cell Depletion TherapyThe Journal of Immunology, 2009
- An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupusArthritis & Rheumatism, 2008
- Transitional Type 1 and 2 B Lymphocyte Subsets Are Differentially Responsive to Antigen Receptor SignalingJournal of Biological Chemistry, 2002